EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives

Dekang Ren, Shizheng Xiong, Yujie Ren, Xueni Yang, Xinmiao Zhao, Jiaming Jin, Miaomiao Xu, Tingming Liang, Li Guo, Lixing Weng

Computational and Structural Biotechnology Journal · 2024-12 · 23 · 1833-1843

DOI: 10.1016/j.csbj.2024.04.054 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 21.04.2024. Verfasst von Dekang Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecom…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preventive cancer vaccines are highly effective in preventing viral infection-induced cancer, but advances in therapeutic cancer vaccines with a focus on eliminating cancer cells through immunotherapy are limited. To develop therapeutic cancer vaccines, the integration of optimal adjuvants is a potential strategy to enhance or complement existing therapeutic approaches. However, conventional adjuvants do not satisfy the criteria of clinical trials for therapeutic cancer vaccines. To improve the effects of adjuvants in therapeutic cancer vaccines, effective vaccination strategies must be formulated and novel adjuvants must be identified. This review offers an overview of the current advancements in therapeutic cancer vaccines and highlights in situ vaccination approaches that can be synergistically combined with other immunotherapies by harnessing the adjuvant effects. Additionally, the refinement of adjuvant systems using cutting-edge technologies and the elucidation of molecular mechanisms underlying immunogenic cell death to facilitate the development of innovative adjuvants have been discussed.

Schlagwörter

Stichwörter der Autor:innen

AdjuvantsImmunogenic cell deathIn situ vaccinationTherapeutic cancer vaccines

Autor:innen und Institutionen

  • State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
  • Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ren, D., Xiong, S., Ren, Y., Yang, X., Zhao, X., Jin, J., Xu, M., Liang, T., Guo, L., & Weng, L. (2024). Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives. Computational and Structural Biotechnology Journal, 23, 1833-1843. https://doi.org/10.1016/j.csbj.2024.04.054

Vancouver

Ren D, Xiong S, Ren Y, Yang X, Zhao X, Jin J, et al. Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives. Computational and Structural Biotechnology Journal. 2024;23:1833-1843. doi:10.1016/j.csbj.2024.04.054

BibTeX
@article{Ren2024,
  author = {Ren, Dekang and Xiong, Shizheng and Ren, Yujie and Yang, Xueni and Zhao, Xinmiao and Jin, Jiaming and Xu, Miaomiao and Liang, Tingming and Guo, Li and Weng, Lixing},
  title = {Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives},
  journal = {Computational and Structural Biotechnology Journal},
  year = {2024},
  volume = {23},
  pages = {1833--1843},
  doi = {10.1016/j.csbj.2024.04.054}
}
Kostenlos starten →